Scaffold hopping in the rational design of novel HIV-1 non-nucleoside reverse transcriptase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 12, 2007, Pages 3362-3366

  O'Meara, Jeff A ^a   Jakalian, Araz ^a   LaPlante, Steven ^a   Bonneau, Pierre R ^a   Coulombe, René ^a   Faucher, Anne Marie ^a   Guse, Ingrid ^a   Landry, Serge ^a   Racine, Jennifer ^a   Simoneau, Bruno ^a   Thavonekham, Bounkham ^a   Yoakim, Christiane ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

NNRTI; Scaffold hopping; Tertiary amide; Tertiary carbamate; Tetrazole thioacetanilide; Thio tetrazole

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; DRUG CONFORMATION; DRUG DESIGN; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

AMIDES; ANTI-HIV AGENTS; CARBAMATES; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, CHEMICAL; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOCARBAMATES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34249327726     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.03.097     Document Type: Article

References (14)

1. Joint United Nations Programme on HIV/AIDS and World Health Organization Aids Epidemic Update 2006.
2. Girardet J.L., De la Rosa M., Kim H.W., Gunic E., Jenket C., Boyle U., et al. Bioorg. Med. Chem. Lett. 16 (2006) 4444
3. Zhang Z., Xu W., Koh Y.H., Shim J.H., Giradet J.L., Yeh L.T., Hamatake R.K., and Hong Z. Antimicrob. Agents Chemother. (2007) 429
4. He Y., Wand A., Wu B., Kuhen K.L., Bursulaya B., Nguyen T.N., and Nguyen D.G. Bioorg. Med. Chem. Lett. 16 (2006) 4174
5. Muraglia E., Kinzel O.D., Laufer R., Miller M.D., Moyer G., et al. Bioorg. Med. Chem. Lett. 16 (2006) 2748
6. Girardet, J. L.; Zhang, Z.; Hamatake, R.; Hernandez M. De la Rosa; Gunic, E.; Hong, Z.; Kim, H. W.; Koh, Y. H.; Nilar, S.; Shaw, S.; Yao, N. Patent WO 2004030611, 2004.
7. Simoneau, B.; Thavonekham, B.; Landry, S.; O'Meara, J.; Yoakim, C.; Faucher, A.-M. Patent WO 2004050643, 2004.
8. Shaw-Reid, C. A.; Miller, M. D.; Hazuda, D. J.; Ferrer, M.; Sur, S. M.; Summa, V.; Lyle, T. A.; Kinzel, O.; Pescatore, G.; Muraglia, E.; Orvieto, F.; Williams, P. D. Patent WO2005115147, 2005.
9. Girardet, J. L.; Koh, Y. H.; Hernandez M. De la Rosa; Gunic, E.; Kim, H. W.; Hong, W. Patent WO 2006026356, 2006.
10. Simoneau, B.; Thavonekham, B.; Landry, S.; O'Meara, J.; Yoakim, C.; Faucher, A.-M. Patent WO 2005118575, 2005.
11. Pelemans H., Esnouf R., De Clercq E., and Balzarini J. Mol. Pharmacol. 57 (2000) 954
12. A patent covering closely related analogs was disclosed during the preparation of this manuscript. Koch, U.; Kinzel, O.; Muraglia, E.; Summa, V. Patent WO 2006037468, 2006.
13. Scaffold hopping has recently been reviewed and defined. Brown, N.; Jacoby, E. Mini Rev. Med. Chem. 2006, 11, 1217.
14. The tetrazole based inhibitors were prepared in a similar route as previously reported in Ref. 2d.